Multicentric, Randomized Phase III Trial of Two Different Adjuvant Chemotherapy Regimens plus Three Versus Twelve Months of Trastuzumab in Patients with HER2-Positive Breast Cancer (Short-HER Trial; NCT00629278)
Keyword(s):
2017 ◽
Keyword(s):
2014 ◽
Vol 32
(15_suppl)
◽
pp. 506-506
◽
Keyword(s):
2018 ◽
Vol 24
(21)
◽
pp. 5292-5304
◽
2015 ◽
Keyword(s):